Anti-obesity peptide and application thereof

An obesity and heptapeptide technology, applied in the field of biopharmaceuticals, can solve the problems of anti-obesity peptide verification, and achieve the effect of reducing lipid accumulation and inhibiting differentiation

Active Publication Date: 2022-04-12
SOUTH CHINA UNIV OF TECH +1
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the in vitro activity of the three potential anti-obesity peptides was not verified during the experiment (Fisayo Ajayi F, Mudgil P, Gan C Y, et al. Identification and characterization of cholesterol esterase and lipase inhibitory peptides from amaranth protein hydrolysates[J]. Food Chem X,2021,12:100165.)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-obesity peptide and application thereof
  • Anti-obesity peptide and application thereof
  • Anti-obesity peptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0097] Add 25 μL of dodecapeptide RGGFLLAMVRAP (RP-12) solution at a concentration of 50 μM to a 96-well black plate, followed by adding 25 μL of pancrelipase solution and 50 μL of 4-methylumbelliferone oleate solution, and incubate at 25°C for 20 minutes in the dark , add 100 μL of sodium citrate solution (0.1M pH=4.2) to stop the reaction, replace the dodecapeptide RGGFLLAMVRAP solution with Tris-HCl buffer as a negative control, and replace the dodecapeptide RGGFLLAMVRAP with Orlistat as a positive control . Tris-HCl buffer was used instead of pancrelipase solution as the background group. After the reaction, record its fluorescence intensity value at the excitation wavelength of 320nm and emission wavelength of 450nm and calculate the inhibition rate of pancreatic lipase.

[0098] Figure 12 Fitting curve for the inhibitory activity of synthetic peptide Arg-Gly-Gly-Phe-Leu-Leu-Ala-Met-Val-Arg-Ala-Pro on pancreatic lipase. Depend on Figure 12 It can be seen that the do...

Embodiment 2

[0100] Add 25 μL of dodecapeptide RGGFLLAMVRAP (RP-12) solution at a concentration of 100 μM to a 96-well black plate, followed by adding 25 μL of pancrelipase solution and 50 μL of 4-methylumbelliferone oleate solution, and incubate at 25°C in the dark for 20 minutes 100 μL of sodium citrate solution (0.1M pH=4.2) was added to stop the reaction, and Tris-HCl buffer was used instead of RGGFLLAMVRAP solution as a negative control, and Orlistat (Orlistat) instead of dodecapeptide RGGFLLAMVRAP was used as a positive control. Tris-HCl buffer was used instead of pancrelipase solution as background. After the reaction, record its fluorescence intensity value at the excitation wavelength of 320nm and emission wavelength of 450nm and calculate the inhibition rate of pancreatic lipase.

[0101] Figure 12 Fitting curve for the inhibitory activity of synthetic peptide Arg-Gly-Gly-Phe-Leu-Leu-Ala-Met-Val-Arg-Ala-Pro on pancreatic lipase. Depend on Figure 12 It can be known that the d...

Embodiment 3

[0103] Add 25 μL of nonapeptide QSAFLHVMY (QY-9) solution at a concentration of 500 μM to a 96-well black plate, followed by 25 μL of pancrelipase solution and 50 μL of 4-methylumbelliferone oleate solution, and incubate at 25°C for 20 minutes in the dark , Add 100 μL of sodium citrate solution (0.1M pH=4.2) to terminate the reaction, use Tris-HCl buffer instead of nonapeptide QSAFLHVMY solution as a negative control, and use Orlistat (Orlistat) instead of nonapeptide QSAFLHVMY as a positive control. Tris-HCl buffer was used instead of pancrelipase solution as background. After the reaction, record its fluorescence intensity value at the excitation wavelength of 320nm and emission wavelength of 450nm and calculate the inhibition rate of pancreatic lipase.

[0104] Figure 13 Fitting curve for the inhibitory activity of synthetic nonapeptide Gln-Ser-Ala-Phe-Leu-His-Val-Met-Tyr on pancreatic lipase. Depend on Figure 13 It can be seen that the nonapeptide QSAFLHVMY with a con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an anti-obesity peptide and application thereof, the amino acid sequences of five peptides are respectively RGGFLLAMVRAP, QSAFLHVMY, FLLWAAL, WLTAMLEWR and WYFPGR, and the peptide provided by the invention is synthesized by using a polypeptide synthesizer and adopting a solid-phase synthesis method. In-vitro activity detection shows that the 50% inhibition concentration of the five peptides to pancreatic lipase is within the range of 5.36-477.24 mu M. Under the concentration of 200 [mu] M, the content of triglyceride TG in 3T3-L1 cells can be reduced from 1.06 + / -0.06 mmol / gprot to 0.17 + / -0.02 to 0.69 + / -0.01 mmol / gprot by the five peptides. The invention provides five synthetic peptides with potential in-vitro anti-obesity activity, which can be applied to the field of biological pharmacy.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, and in particular relates to an anti-obesity peptide and its application. Background technique [0002] In recent decades, the level of the global economy has continued to grow rapidly, and people's quality of life has also continued to improve. But what follows is the acceleration of people's life rhythm - high-calorie fast food diet, unhealthy life schedule and reduced exercise. This way of life has caused more and more people to fall into the swamp of obesity. Obesity not only affects people's quality of life, but also increases the risk of cardiovascular disease, atherosclerosis, hypertension and other metabolic diseases, threatening people's health at all times. Obesity is mainly due to the imbalance between the body's energy intake and body's energy consumption, resulting in excessive fat accumulation. According to research, obesity is closely related to the activity of enzymes in the di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C07K7/08C07K1/16C07K1/06C07K1/04A61K38/08A61K38/10A61P3/04A61P3/06
Inventor 张学武赵冰丽万泽民
Owner SOUTH CHINA UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap